Interestingly, ZC-22 displayed a better anti-tumor efficacy than the Olaparib and Abemaciclib monotherapy, and the combination therapy in cell culture models (Figure 2B), suggesting that ZC-22 was a potential alternative for the PARPi and CDK4/6i combination therapy. Here, CDK4 is linked to neoplasm.